HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,741,844 | +6.6% | 45,598 | +0.6% | 0.04% | +15.2% |
| Q2 2023 | $1,634,368 | -6.1% | 45,311 | -0.6% | 0.03% | -5.7% |
| Q1 2023 | $1,741,311 | -30.2% | 45,596 | +3.9% | 0.04% | -31.4% |
| Q4 2022 | $2,495,862 | +77.8% | 43,864 | +23.5% | 0.05% | +70.0% |
| Q3 2022 | $1,404,000 | -8.2% | 35,512 | +2.1% | 0.03% | +3.4% |
| Q2 2022 | $1,530,000 | +39.9% | 34,770 | +26.7% | 0.03% | +70.6% |
| Q1 2022 | $1,094,000 | -2.8% | 27,439 | -1.9% | 0.02% | +6.2% |
| Q4 2021 | $1,125,000 | +4.4% | 27,978 | +5.6% | 0.02% | 0.0% |
| Q3 2021 | $1,078,000 | -4.4% | 26,492 | +6.7% | 0.02% | -5.9% |
| Q2 2021 | $1,128,000 | +26.7% | 24,831 | +16.2% | 0.02% | +21.4% |
| Q1 2021 | $890,000 | +20.9% | 21,360 | +23.9% | 0.01% | +16.7% |
| Q4 2020 | $736,000 | +260.8% | 17,233 | +122.5% | 0.01% | +200.0% |
| Q3 2020 | $204,000 | +83.8% | 7,745 | +86.3% | 0.00% | +100.0% |
| Q2 2020 | $111,000 | – | 4,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |